Wellington Partners has announced the final close of its fifth-generation fund Wellington Partners Life Science Fund V (WPLS-V).  

Thriva, the proactive health company, has secured a £6M Series A funding round. The funding will support Thriva as it builds towards it’s ambitious vision: to put optimal health in anyone’s hands.  The round, from a range of investors including Pembroke VCT and Guinness Asset Management, takes the total raised by Thriva to £7.5m since its launch in 2016.  Thriva offers affordable, clinical-grade insights based on the latest research and has helped over 100,000 people understand how their lifestyle is impacting their health.

The Animal Health Laboratory within the Colorado Department of Agriculture is assisting in a trial of Actiphage®, a new rapid blood test for 

Bluecrest Health Screening, a leading provider of affordable health checks, has secured a £17 million investment arranged by private equity firm Vespa Capital.

PredictImmune, developers of pioneering prognostic tools for guiding treatment options and improving patient outcomes in immune-mediated diseases, has announced the completion of its Series B funding having raised £10M.

Keensight Capital, one of the leading private equity managers dedicated to pan-European Growth Buyout[1] investments, announces the acquisition of Infarco’s majority stake in 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in the process development and GMP manufacturing of biologics.

Medical device company Flow, creators of the first and only medically approved treatment for depression of its kind in Europe, today announces it has raised $1.5m in an investment round led by Khosla Ventures to tackle the world’s most urgent mental health challenges. The investment will be used to support Flow’s European rollout, introduce Flow to healthcare clinics, and fund clinical studies.

Foresight Group has invested a further £4 million growth capital investment into portfolio company ONFAB to fund the acquisition of Lancashire based designer and manufacturer of clean air containment products, Envair Holdings Limited.

ONFAB produces flexible clean-air enclosures and consumables, designed and manufactured in-house from sites in Cheshire and Spain. Founded in 2005 by Oliver Nulty, ONFAB received investment from the £60 million Foresight Regional Investment LP fund in September 2017 to facilitate a majority buyout of the business. Since then, with an enlarged team and renewed focus on sales, margins and new products, it has grown by over 30% per year and continues to benefit from ever stricter safety standards protecting workers across the globe.

Asabys Partners, a Pan-European Venture Capital firm specialized in investments in the life sciences and health sectors, and Alantra, an investment banking and asset management firm, have reached an agreement by which Alantra becomes a strategic partner of Asabys through the acquisition of a 35% stake in the firm.

The transaction has the support of Banc Sabadell as one of the promoters of the project and anchor investor in Asabys’ first vehicle ("Sabadell Asabys Health Innovation Investments SCR SA"). As part of the agreement, Alantra will invest in the first vehicle of Asabys and will support the search for new investors and the internationalization of the project.

Luminous Ventures has made a £1million investment in Optellum, developers of the world’s first AI clinical diagnosis support software for personalized early lung cancer diagnosis and treatment.

Aergo, a company that has developed a responsive posture support system which empowers wheelchair users, ahas completed an equity funding round with the help of ClearlySo, Europe’s leading impact investment bank. The funding will go towards expanding the team and product manufacturing and piloting.

Vesalius Biocapital III, the specialist life sciences venture capital investor, has closed its VBC III fund securing EUR 120 million of equity commitments. This includes commitments of EUR 30 million from the European Investment Fund (EIF) and new and existing investors from Europe, the Americas and MENA. The fund is a validation of Vesalius’ proven approach to invest in later-stage European life sciences companies, providing capital to support their development. Vesalius Biocapital III has executed three investments to date.